Assenagon Asset Management S.A. Reduces Stake in Collegium Pharmaceutical, Inc. $COLL

Assenagon Asset Management S.A. decreased its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 38.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 312,598 shares of the specialty pharmaceutical company’s stock after selling 199,100 shares during the period. Assenagon Asset Management S.A. owned 0.96% of Collegium Pharmaceutical worth $10,338,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of COLL. Janus Henderson Group PLC grew its position in shares of Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after acquiring an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Collegium Pharmaceutical by 65.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock valued at $60,776,000 after buying an additional 518,721 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock valued at $19,338,000 after buying an additional 461,914 shares during the last quarter. Two Sigma Investments LP boosted its stake in shares of Collegium Pharmaceutical by 897.2% during the third quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company’s stock worth $9,423,000 after buying an additional 242,310 shares during the period. Finally, Qube Research & Technologies Ltd grew its holdings in shares of Collegium Pharmaceutical by 237.9% during the third quarter. Qube Research & Technologies Ltd now owns 320,559 shares of the specialty pharmaceutical company’s stock worth $11,216,000 after buying an additional 225,679 shares during the last quarter.

Analyst Upgrades and Downgrades

COLL has been the topic of several recent research reports. Needham & Company LLC reissued a “buy” rating and issued a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a research note on Thursday, March 19th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Weiss Ratings lowered shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Wall Street Zen raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, Collegium Pharmaceutical has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Trading Up 5.0%

COLL stock opened at $36.59 on Friday. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 17.94 and a beta of 0.74. The business has a fifty day simple moving average of $34.08 and a 200-day simple moving average of $39.67. Collegium Pharmaceutical, Inc. has a 52 week low of $29.19 and a 52 week high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. During the same period in the previous year, the firm posted $1.49 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts expect that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.